Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Monday, May 5th. Analysts expect Rocket Pharmaceuticals to post earnings of ($0.59) per share and revenue of $0.80 million for the quarter.
Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) EPS for the quarter, topping analysts' consensus estimates of ($0.68) by $0.06. On average, analysts expect Rocket Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Rocket Pharmaceuticals Stock Performance
Shares of NASDAQ:RCKT traded up $0.15 during midday trading on Friday, reaching $8.01. The company had a trading volume of 2,036,907 shares, compared to its average volume of 1,355,447. Rocket Pharmaceuticals has a 52-week low of $4.55 and a 52-week high of $26.98. The company's 50 day moving average price is $7.37 and its 200 day moving average price is $11.03. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. The stock has a market cap of $855.36 million, a P/E ratio of -2.91 and a beta of 1.02.
Analysts Set New Price Targets
RCKT has been the subject of several research analyst reports. The Goldman Sachs Group decreased their price target on shares of Rocket Pharmaceuticals from $29.00 to $15.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. BMO Capital Markets assumed coverage on Rocket Pharmaceuticals in a research note on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 target price on the stock. Canaccord Genuity Group cut their price target on Rocket Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating for the company in a research note on Monday, March 3rd. Scotiabank boosted their price objective on Rocket Pharmaceuticals from $51.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Monday, March 3rd. Finally, Chardan Capital reduced their target price on shares of Rocket Pharmaceuticals from $62.00 to $54.00 and set a "buy" rating for the company in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Rocket Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $43.00.
Get Our Latest Analysis on Rocket Pharmaceuticals
Insider Buying and Selling at Rocket Pharmaceuticals
In other Rocket Pharmaceuticals news, insider Kinnari Patel acquired 21,099 shares of the business's stock in a transaction dated Wednesday, April 9th. The stock was bought at an average price of $4.70 per share, with a total value of $99,165.30. Following the completion of the acquisition, the insider now owns 26,774 shares of the company's stock, valued at $125,837.80. This trade represents a 371.79 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Aaron Ondrey sold 7,489 shares of the firm's stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $5.29, for a total transaction of $39,616.81. Following the completion of the sale, the chief financial officer now directly owns 129,650 shares in the company, valued at $685,848.50. This represents a 5.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 28.50% of the company's stock.
About Rocket Pharmaceuticals
(
Get Free Report)
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Further Reading
Before you consider Rocket Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rocket Pharmaceuticals wasn't on the list.
While Rocket Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
